Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RMC-4550 + RMC-4998 + unspecified CTLA4 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RMC-4550 | RMC4550|RMC 4550 | SHP2 Inhibitor 20 | RMC-4550 is a small molecule allosteric inhibitor of Shp2 that blocks Ras-Raf-Mek-Erk pathway signaling, leading to tumor growth inhibition (PMID: 30104724). | |
RMC-4998 | RMC4998|RMC 4998 | KRAS G12C inhibitor 34 | RMC-4998 is a small molecule that selectively inhibits active KRAS G12C by forming a tri-complex with KRAS G12C and cyclophilin A, potentially resulting in decreased RAS signaling and tumor cell proliferation, and reduced tumor growth (PMID: 37590355). | |
unspecified CTLA4 antibody | experimental CTLA4 antibody | Immune Checkpoint Inhibitor 149 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|